The current opioid epidemic has spread rapidly through the United States, resulting in an exponential increase in opioid-associated deaths, transmission of infectious diseases, and a social crisis, which includes a sharp increase in the number of children in foster care because of parental neglect, incapacity, and/or overdose. To stem this tide, public health initiatives must address the treatment needs of more than 11 million people aged 12 years and older who misuse opioids, including the shortage of practitioners to treat those with opioid use disorder (OUD). 1,2 Currently, there are 3 highly effective medicationassisted treatments for OUD: the μ-opioid receptor agonist methadone, the antagonist naltrexone (in oral and long-acting injectable forms), and the partial agonist buprenorphine (used mainly as combination buprenorphinenaloxone). Methadone must be dispensed in a federally licensed facility, and therefore access is limited. Naltrexone requires detoxification prior to initiation, while treatment with buprenorphine can be provided without detoxification in an office-based setting. Thus, buprenorphine provides a means to rapidly expand treatment capacity. Treatment with buprenorphine has been shown to decrease illicitopioiduse,overdosedeaths,HIVandhepatitisCtransmission,andcriminalbehaviorandimprovesocialfunctioning in individuals with OUD. 1 A national movement to train physicians to provide treatment with buprenorphine, particularly among primary care physicians, has resulted in a significant increase in buprenorphine prescribing by this group. With the shift to prescribing in primary care settings, the relative percentage of prescriptions prescribed by psychiatrists declined from 92.2% in 2003 to 32.8% by 2013. 3 The increased prescribing of buprenorphine by primary care physicians is a welcome development because treatment of OUD should be shared among physicians across all specialties. However, we believe psychiatrists could do more in response to this public health crisis. General psychiatrists do not routinely incorporate addiction treatment in their practice, and a national survey of psychiatrists indicates that more than 80% were uncomfortable with providing office-based opioid treatment. 4 We believe psychiatrists are uniquely skilled and ideally suited to be leaders in treating this epidemic. Psychiatry as a field was the first to recognize the need for training in addiction within graduate medical education. In addition, psychiatrists are knowledgeable about neurobiology and psychological principles underlying behavior and the treatment of behavioral disorders. Moreover, the treatment of OUD is often complicated by the high prevalence of comorbid psychiatric disorders, which also influence adherence to buprenorphine treatment. 5